CALML6 Controls TAK1 Ubiquitination and Confers Protection against Acute Inflammation

Chunjie Sheng,Ziyang Wang,Chen Yao,Hui-Ming Chen,Guangyan Kan,Dan Wang,Hongyuan Chen,Shuai Chen
DOI: https://doi.org/10.4049/jimmunol.1901042
2020-06-01
Abstract:Proper regulation of innate immune response is important for individual health. The NF-κB signaling pathway plays crucial roles in innate immunity and inflammation, and its aberrant activation is implicated in diverse diseases and disorders. In this study, we report that calmodulin-like 6 (CALML6), a member of the EF-hand protein family, is a negative regulator of the NF-κB signaling pathway. CALML6 attenuated TNF-stimulated phosphorylation of proteins downstream of TGF-β-activated kinase 1 (TAK1) and inhibited TAK1-induced NF-κB activation. Further studies showed that CALML6 interacted with TAK1 and recruited the deubiquitylating enzyme cylindromatosis to repress the K63-linked polyubiquitination of TAK1. CALML6 transgenic mice had higher tolerances to lethal LPS treatment in vivo. These findings suggest that CALML6 is a negative regulator of the NF-κB signaling pathway, which is important for maintaining the balance of the innate immune response.
What problem does this paper attempt to address?